Abstract n.4581. Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development UTUC and BUC represent distinct tumor entities that may deserve dedicated therapeutic strategies, in particular with the availability of several clinical studies of targeted therapies or immunotherapy. To understand the genomic landscape and inform the therapeutic development of UC, 2463 cases (479 UTUC and 1984 BUC) were analyzed by CGP for genomic alterations (GAs) and for genome wide signatures.
• ≥50 ng DNA extracted from 40 µm of FFPE sections • Sequencing performed for up to 315 cancer-related genes and introns from 28 genes commonly rearranged in cancer • Hybrid capture-based sequencing using adaptor ligation-based libraries • Mean coverage depth >600X • Base substitutions, insertions and deletions (short variants; SV), rearrangements, and copy number changes were assessed [1, 2] • Tumor mutational burden (TMB) calculated from 1.14 Mb sequenced DNA [1, 2] • Hybrid capture-based genomic profiling of cell-free DNA (cfDNA) was performed on ≥20 ng of cfDNA and sequencing was performed on up to 70 genes (FoundationOne Liquid) [3] to a mean unique coverage depth of >8,000X.
• For comparison of paired tissue and circulating tumor DNA (ctDNA) samples, concordance was evaluated for baited regions common to both CGP assays.
• Targetable GA and signatures were assessed according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) [4] • Against a background of 50% actionability in UC with opportunities for immunotherapy, TT, or combinations thereof, the UTUC cohort is enriched for FGFR3 and HRAS SV relative to BUCHRAS mutations predominantly in UC of the renal pelvis, that warrants further investigation into the distinct modes of oncogenesis for UC as stratified by anatomic origin.
• Liquid biopsy-based genomic profiling identified targetable FGFR3 alterations. 73% of mutations present in matched tissue samples were also detected in paired liquid biopsy samples (<180 day time interval).
• These results argue strongly for the routine incorporation of CGP prior to systemic therapy initiation in metastatic UC.
Targetable genomic alterations and signatures identified in BUC and UTUC.
Genomic alterations were ranked using the ESCAT actionability scale. Each case was assigned a tier according to the highest ranked genomic alteration/signature. ESCAT rankings were performed with and without TMB/MSI genomic signatures considered on the actionability scale. Concordance was evaluated as positive-percent agreement (PPA) with tissue as a reference and as % of all detected mutations that were shared.
• Frequency and distribution of targetable FGFR3 mutations were similar between tissue and ctDNA • Concordance varied with time interval between tissue and blood collection.
• For samples with a time interval of <180 days between sample collection, there was a 73% PPA to tissue and 90% of cases shared at least 1 mutation. BRAF fusions and mutations comprise a potentially targetable genomic subset BRAF fusion or mutation was observed in 2% of UC cases and were mutually exclusive with FGFR3 GAs. Details of BRAF fusions and mutations shown.
